NYSE:HUM - Humana Stock Price, Forecast & News

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Humana announced a quarterly dividend on Friday, February 21st. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.625 per share on Friday, April 24th. This represents a $2.50 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend is Monday, March 30th. This is an increase from Humana's previous quarterly dividend of $0.55. View Humana's Dividend History.

Humana Inc (NYSE:HUM) announced its earnings results on Wednesday, February, 5th. The insurance provider reported $2.28 EPS for the quarter, topping the consensus estimate of $2.20 by $0.08. The insurance provider had revenue of $16.30 billion for the quarter, compared to the consensus estimate of $16.15 billion. Humana had a net margin of 4.17% and a return on equity of 20.89%. The business's revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter last year, the company posted $2.65 earnings per share. View Humana's Earnings History.

Humana is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Humana.

Humana updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share (EPS) guidance of $18.25-18.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $18.63.

17 analysts have issued 1-year target prices for Humana's stock. Their forecasts range from $290.00 to $460.00. On average, they expect Humana's share price to reach $384.00 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for Humana.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.

News articles about HUM stock have been trending very negative on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Humana earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the insurance provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Humana.

Humana saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,930,000 shares, a decline of 11.5% from the January 15th total of 2,180,000 shares. Based on an average trading volume of 934,800 shares, the days-to-cover ratio is presently 2.1 days. Approximately 1.5% of the shares of the stock are short sold. View Humana's Current Options Chain.

Some companies that are related to Humana include UnitedHealth Group (UNH), Cigna (CI), Anthem (ANTM), Centene (CNC), WellCare Health Plans (WCG), Molina Healthcare (MOH), Magellan Health (MGLN) and Triple-S Management (GTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Mastercard (MA), Visa (V), Boeing (BA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Cigna (CI).

Humana's stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital International Investors (7.58%), Capital Research Global Investors (5.91%), FMR LLC (4.71%), State Street Corp (4.36%), Capital World Investors (3.92%) and Renaissance Technologies LLC (2.23%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James J /Ky Obrien, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.

HUM stock was sold by a variety of institutional investors in the last quarter, including GQG Partners LLC, Ceredex Value Advisors LLC, Maverick Capital Ltd., Janus Henderson Group PLC, Marshall Wace North America L.P., Marshall Wace LLP, FMR LLC and Point72 Asset Management L.P.. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Christopher H Hunter, Elizabeth D Bierbower, James J /Ky Obrien, Timothy Alan Wheatley and Timothy S Huval. View Insider Buying and Selling for Humana.

HUM stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, AQR Capital Management LLC, Man Group plc, Capital World Investors, Boston Partners, First Trust Advisors LP, Panagora Asset Management Inc. and Schroder Investment Management Group. View Insider Buying and Selling for Humana.

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HUM stock can currently be purchased for approximately $369.67.

Humana has a market capitalization of $48.84 billion and generates $64.89 billion in revenue each year. The insurance provider earns $2.71 billion in net income (profit) each year or $17.87 on an earnings per share basis. Humana employs 41,600 workers across the globe.View Additional Information About Humana.

The official website for Humana is http://www.humana.com/.

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]